You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Drug Price Trends for ARNUITY ELLIPTA


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for ARNUITY ELLIPTA

Best Wholesale Price for ARNUITY ELLIPTA

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
ARNUITY ELLIPTA 100MCG GlaxoSmithKline 00173-0874-14 14 67.57 4.82643 EACH 2024-01-01 - 2027-07-31 FSS
ARNUITY ELLIPTA 50MCG/ACTUAT INHL,ORAL,30 GlaxoSmithKline 00173-0888-10 30 134.12 4.47067 EACH 2022-08-01 - 2027-07-31 Big4
ARNUITY ELLIPTA 100MCG GlaxoSmithKline 00173-0874-10 30 164.80 5.49333 EACH 2024-01-01 - 2027-07-31 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for ARNUITY ELLIPTA

Introduction to ARNUITY ELLIPTA

ARNUITY ELLIPTA, marketed by GlaxoSmithKline (GSK), is an inhaled corticosteroid (ICS) containing the active ingredient fluticasone furoate. It is approved by the FDA for the once-daily maintenance treatment of steroid-responsive bronchial asthma in patients aged 12 and older[1][3].

Current Market Position

ARNUITY ELLIPTA is currently available only as a brand-name drug, with no generic version available in the market. The drug is delivered via a dry powder breath-actuated inhaler, Ellipta, and comes in two strengths: 100 mcg and 200 mcg per inhalation[3].

Pricing and Cost Analysis

The pricing of ARNUITY ELLIPTA varies based on the dosage and quantity. Here are some current price points:

  • 100 mcg: Approximately $111.95 for a 14-dose inhaler, translating to about $8.00 per dose[2].
  • 200 mcg: Approximately $146.66 for a 14-dose inhaler, translating to about $10.48 per dose[2].

These prices are for cash-paying customers and do not reflect prices with insurance coverage. The cost can be significantly reduced using discount cards or patient assistance programs[2].

Pharmacoeconomic Review

A pharmacoeconomic review by the Common Drug Review (CDR) compared the costs of ARNUITY ELLIPTA with other inhaled corticosteroids (ICS) and ICS/LABA combinations. The review indicated that while ARNUITY ELLIPTA is more costly than some low-dose ICSs, it offers cost savings compared to medium and high-dose ICSs in certain scenarios. For example, the annual cost of ARNUITY ELLIPTA 100 mcg is lower than that of fluticasone propionate (FP) 500 mcg, but higher than some other ICSs like budesonide 400 mcg[3].

Patent and Exclusivity Status

ARNUITY ELLIPTA is protected by three patents in the US and forty-six patent family members in twenty-one countries. The earliest estimated date for generic entry is March 1, 2026, although this could change due to patent challenges or licensing agreements. There have been two patent litigation cases, indicating strong interest in a generic launch[1].

Market Impact of Generic Entry

The potential entry of generic versions in 2026 is expected to significantly impact the market dynamics for ARNUITY ELLIPTA. Historically, 63% of patent challenges are decided in favor of the generic patent challenger, and 54% of successful challengers promptly launch generic drugs. This could lead to a substantial reduction in the market share and revenue for the brand-name version of ARNUITY ELLIPTA[1].

Competitive Landscape

The respiratory market, particularly for asthma treatments, is highly competitive. ARNUITY ELLIPTA competes with other ICS and ICS/LABA combination products such as fluticasone propionate/salmeterol (Advair) and budesonide/formoterol (Symbicort). GSK's own portfolio, including Trelegy and Anoro, also plays a significant role in this market[4].

Price Projections

Given the upcoming generic entry, the prices of ARNUITY ELLIPTA are likely to decrease significantly. Here are some potential price projection scenarios:

  • Pre-Generic Entry (2024-2026): Prices are expected to remain relatively stable, with potential minor adjustments based on market conditions and competition.
  • Post-Generic Entry (2026 and beyond): Prices could drop by 50-80% as generic versions enter the market, leading to increased competition and reduced market share for the brand-name product.
  • Discounts and Patient Assistance Programs: To mitigate the impact of generic entry, GSK might enhance discount programs, copay cards, and patient assistance initiatives to retain market share and patient loyalty[2].

GSK's Strategic Response

GSK is likely to focus on several strategies to maintain its market position:

  • Pipeline Development: GSK has a strong pipeline of respiratory and immunology products, including new treatments for severe asthma and COPD. This could help offset the impact of generic competition[4].
  • Market Access and Reimbursement: GSK will likely work to maintain favorable reimbursement and market access for ARNUITY ELLIPTA, especially in key markets.
  • Brand Loyalty Programs: Enhancing patient loyalty programs and educational initiatives to retain patients on the brand-name medication.

Key Takeaways

  • ARNUITY ELLIPTA is a significant player in the asthma treatment market but faces imminent generic competition.
  • Current pricing is around $111.95 for a 14-dose inhaler of the 100 mcg strength and $146.66 for the 200 mcg strength.
  • Generic entry in 2026 is expected to significantly reduce prices and market share.
  • GSK will likely employ various strategies to maintain market presence, including pipeline development and enhanced patient programs.

FAQs

Q: What is the current price range for ARNUITY ELLIPTA? A: The current price range is approximately $111.95 for a 14-dose inhaler of the 100 mcg strength and $146.66 for the 200 mcg strength.

Q: When is the generic version of ARNUITY ELLIPTA expected to enter the market? A: The generic version is expected to enter the market around March 1, 2026.

Q: How will generic entry affect the price of ARNUITY ELLIPTA? A: Prices are likely to drop by 50-80% post-generic entry due to increased competition.

Q: What strategies might GSK employ to maintain market share? A: GSK may focus on pipeline development, market access, reimbursement strategies, and brand loyalty programs.

Q: Is ARNUITY ELLIPTA available in different strengths? A: Yes, it is available in 100 mcg and 200 mcg strengths.

Cited Sources

  1. Drug Patent Watch: ARNUITY ELLIPTA Drug Patent Profile.
  2. Drugs.com: Arnuity Ellipta Prices, Coupons, Copay Cards & Patient Assistance.
  3. Common Drug Review: Pharmacoeconomic Review Report for Arnuity Ellipta.
  4. GSK: Q4 2023 Announcement - GSK.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.